Restricted TRBV repertoire in CD4⁺ and CD8⁺ T‐cell subsets from CML patients

Figures & data

Table 1. Clinical data of CML patients

No.	Sex	Age (years)	WBC (×10^9/l)	Blast+promyelocyte cells (%)	Platelets (×10^9/l)	CD3^+ (%)
C1	F	49	213·59	9	147	24·56
C2	M	16	351·16	0	345	5·84
C3	M	58	59·93	6	144	12·82
C4	M	20	124	0	605	30·0
C5	M	25	256·82	6	109	13·8
C6	M	15	333·95	8·5	208	10·8
C7	F	31	294·91	3	252	10·46
C8	M	30	118·55	5	440	9·6
C9	M	24	244·05	9	750	12·04
C10	M	61	279	10	993	11·8
C11	F	30	99·8	6·5	378	2·1
C12	M	38	103·66	1	181	10·4
C13	F	20	450·45	1	396	12·1
C14	M	42	81·6	6	85	14·18
C15	M	73	196	8	1531	9·1
C16	M	31	129	3·5	285	28·4
C17	M	22	76·6	5·5	171	9·17
C18	M	20	112·7	5	596	24
C19	F	19	7	4	125	28

Figure 1. The frequency of TRBV subfamilies in PBMCs, CD4⁺ and CD8⁺ T cells from 19 CML patients. TRBV13 were used most frequently.

Figure 2. CDR3 analysis of TRBV families in (A) PBMCs, (B) CD4⁺ and (C) CD8⁺ T cells from one CML case (C12). Clonally expanded T cells can be seen in families: BV11 (A, C), BV6 (B, C) and BV21 (B).

Figure 3. Clonality pattern of expressed TRBV subfamilies from (A) PBMCs, (B) CD4⁺ and (C) CD8⁺ T cells in patients with CML. C1–C19: 19 cases with CML; BV1–BV24: TRBV1–TRBV24 subfamilies.

Figure 4. The correlation analysis between the percentage of blast+promyelocyte cells in PBMCs and the TRBV subfamily number in PBMCs, CD4⁺ and CD8⁺ T cells.